secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001367644-22-000141
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions Q3 revenues down 27% to $240M; net loss widens to $75.7M; guidance slashed
--------------------------------------------------------------------------------

- Total revenues $240M (-27% YoY); net loss $75.7M (-$1.52 EPS) vs loss $32.7M (-$0.61) prior year.
- Segment: Products revenue $186.2M (-31%); Services CDMO $36.4M (-13%); nasal naloxone -34%, ACAM2000 -39%, anthrax vaccines +55%.
- Completed TEMBEXA acquisition from Chimerix; BARDA contract up to $680M for 1.7M doses over 10 years.
- FY2022 guidance revised down: total rev $1.05-1.1B (from $1.15-1.25B); adj EBITDA $0-30M (from $80-120M); ACAM2000 cut to $63M.
- Gross margin improved to 33% from 30%; adjusted gross margin 34% from 31%; attributed to mix shift.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764422000141/0001367644-22-000141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764422000141/ebs-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001367644-22-000141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer